Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
Executive Summary
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
You may also be interested in...
‘Weight Management’ Guidance Changes From FDA Could Tip Scales In Obesity Reimbursement Debate
Expected revision to the 2007 draft might more clearly communicate that obesity is a disease than the earlier guidance, and could provide advice on getting indications for treating complications. If US FDA embraces the new thinking, it could help build the case for Medicare reimbursement.
US Launch Of Sensipar Generics May Await Patent Case Even After FDA Approval
Aurobindo remains embroiled in litigation with Amgen on a Sensipar formulation patent, while Cipla settled ahead of bench trial. Generic firms won approval of cinacalcet generics after two federal courts denied Amgen's emergency request for an injunction in dispute with FDA over pediatric exclusivity.
US Launch Of Sensipar Generics May Await Patent Case Even After FDA Approval
Aurobindo remains embroiled in litigation with Amgen on a Sensipar formulation patent, while Cipla settled ahead of bench trial. Generic firms won approval of cinacalcet generics after two federal courts denied Amgen's emergency request for an injunction in dispute with FDA over pediatric exclusivity.